Lookup NU author(s): Dr Iwo Bohr,
Dr Iryna Ziabreva,
Professor Ian McKeith,
Emeritus Professor Robert Perry,
Dr Dag Aarsland,
Dr Jennifer Court
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Antibodies raised against human alpha 2-6 and beta 2-4 nicotinic receptor subunits were utilized to fractionate H-3-epibatidine binding in human temporal cortex and striatum. The predominant receptor subtypes in both regions contained alpha 4 and beta 2 subunits. In normal cortex, 10% of binding was also associated with alpha 2 subunits, whereas in the striatum, contributions by alpha 6 (17%) and beta 3 (23%) were observed. Minimal binding (<= 5%) was associated with alpha 3. In Alzheimer's disease and dementia with Lewy bodies, cortical loss of binding was associated with reductions in alpha 4 (50%, P < 0.01) and beta 2 (30-38%, P < 0.05). in Parkinson's disease and dementia with Lewy bodies, striatal deficits in alpha 6 (91 and 59% respectively, P < 0.01) and beta 3 (72 and 75%, P < 0.05) tended to be greater than for alpha 4 and beta 2 (50-58%, P < 0.05). This study demonstrates distinct combinations of subunits contributing to heteromeric nicotinic receptor binding in the human brain that are area/pathway specific and differentially affected by neurodegeneration. (c) 2006 Elsevier Inc. All rights reserved.
Author(s): Gotti C, Moretti M, Bohr I, Ziabreva I, Vailati S, Longhi R, Riganti L, Gaimarri A, McKeith IG, Perry RH, Aarsland D, Larsen JP, Sher E, Beattie R, Clementi F, Court JA
Publication type: Article
Publication status: Published
Journal: Neurobiology of Disease
ISSN (print): 0969-9961
ISSN (electronic): 1095-953X
Publisher: Academic Press
Altmetrics provided by Altmetric